Ibdenc

07/11/2025

05/11/2025

The AIG IUS Foundation — India’s first, week-long dedicated course on Intestinal Ultrasound — continued with an exciting and knowledge-packed third day!
Participants explored IUS in Crohn’s Disease, engaged in hands-on scanning sessions, and concluded the day with a special Tête-à-Tête with Dr. D. Nageshwar Reddy, gaining inspiring insights from his journey and vision.
🎓 An enriching day of skill, mentorship, and clinical excellence.

05/11/2025

The AIG IUS Foundation — India’s first, week-long dedicated course on Intestinal Ultrasound — continued with an insightful and engaging second day.
Participants explored IUS in Ulcerative Colitis, participated in hands-on workshops, and concluded the day with an informative session with the Stalwarts — gaining valuable perspectives from leading experts in gastroenterology.
🎓 A day of learning, practice, and inspiration for the next generation of IUS experts.

04/11/2025

Day 1 Highlights | IUS Foundation Course at AIG Hospitals, Hyderabad
An inspiring start to the AIG IUS Foundation Course, India’s first, week-long dedicated course on Intestinal Ultrasound!
Participants explored the fundamentals of IUS through engaging sessions, hands-on learning, and interactive discussions - setting the tone for a week of innovation and collaboration.
🎓 Empowering clinicians with knowledge and skills in IUS for better IBD care.

31/10/2025

This month, our spotlight is on combination therapy - the evolving frontier in IBD management.
From classic benchmarks to cutting-edge dual biologic strategies, these pivotal studies are shaping how we approach treatment in ulcerative colitis (UC) and Crohn’s disease (CD).
Featured Highlights:
🔹SONIC (NEJM) – Infliximab + Azathioprine in CD
🔹UC SUCCESS (Gastroenterology) – Infliximab + Azathioprine in UC
🔹COMMIT (Gastroenterology) – Infliximab + Methotrexate in CD
🔹DIAMOND (JCC) – Adalimumab + Azathioprine in CD
🔹VEGA (The Lancet G&H) – Guselkumab + Golimumab in UC
🔹EXPLORER (CGH) – Vedolizumab + Adalimumab + Methotrexate in CD
🔹VETO (AP&T) – Vedolizumab + Tofacitinib in UC

Together, these landmark trials illustrate the growing importance of synergistic therapies to deepen remission and improve outcomes.

🌐Read more and stay updated: www.ibdenc.org

26/09/2025

⏰ Last chance to register!
Join the AIG IUS Preceptorship in IBD – Nov 3–7, 2025.
Asia’s 1st IUS-Dedicated Center 🌏
Apply before Sept 30 👉 https://forms.office.com/r/uFLBV2HGre

09/09/2025

🌏 Asia’s First IUS-Dedicated Center 🌏
IBDENC invites you to the AIG IUS Preceptorship in IBD – Foundation Course, hosted at AIG Hospitals, Hyderabad.

📅 Important Dates:
⏳ Last Date to Apply: 30th September 2025
📚 Course Dates: 3rd – 7th November 2025

An exclusive opportunity to learn from global experts in IUS for IBD.

🔗 Register here: https://forms.office.com/r/uFLBV2HGre

04/09/2025

🔬 IBD-ENC Editorial Picks – September 2025
This month’s spotlight features landmark head-to-head trials in Crohn’s disease (CD) and ulcerative colitis (UC).
From VARSITY and SEAVUE to VIVID-1, HIBISCUS, GALAXI, GARDENIA, SEQUENCE… and more.
Exploring how biologics like vedolizumab, ustekinumab, guselkumab, risankizumab, mirikizumab, adalimumab, and infliximab compare in efficacy and safety.
👉 Stay informed. Stay ahead.
🌐 www.ibdenc.org

11/08/2025

🔰Our Editorial Recommendations – August 2025
🔗 https://www.ibdenc.org/ibd-journalscan
👉This month’s spotlight is on combination therapy breakthroughs in IBD:
💊 Infliximab + Azathioprine (CD & UC)
💊 Guselkumab + Golimumab (UC)
💊 Infliximab + Methotrexate (CD)
💊 Vedolizumab + Adalimumab + Methotrexate (CD)
💊 Adalimumab + Azathioprine (CD)
💊 Vedolizumab + Tofacitinib (UC)
🌐Stay updated, stay ahead.
👉Visit: www.ibdenc.org for more details.